Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events-Reference-Cited by-同舟云学术

Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events

Published:2018-02-01 Issue:4 Volume:6 Page:402-408
ISSN:2326-6066
Container-title:Cancer Immunology Research
language:en
Short-container-title:Cancer Immunol Res

Author:

Martini Dylan J.,Hamieh Lana,McKay Rana R.,Harshman Lauren C.,Brandao Raphael,Norton Craig K.,Steinharter John A.,Krajewski Katherine M.,Gao Xin,Schutz Fabio A.,McGregor Bradley,Bossé Dominick,Lalani Aly-Khan A.,De Velasco Guillermo,Michaelson M. Dror,McDermott David F.,Choueiri Toni K.

Funder

Foundation for the National Institutes of Health (FNIH)

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Immunology

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stage IV renal cell carcinoma achieves pathologic complete response after two ipilimumab plus nivolumab courses despite severe immune-related adverse events: a case report;Journal of Pharmaceutical Health Care and Sciences;2024-05-31

2. Kick-Starting Molecular Theranostics in Renal Cell Carcinoma;Journal of Nuclear Medicine;2024-05

3. Aortic rupture following acute aortitis in a patient with head and neck carcinoma treated with nivolumab: a rare but severe immune-related adverse event;European Archives of Oto-Rhino-Laryngology;2024-02-03

4. Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review;Cancer Treatment Reviews;2024-01

5. Discontinuation of Immune-oncology Combinations due to Immune-related Adverse Events in Patients With Advanced Renal Cancers;Anticancer Research;2023-12-30